This phase I/II trial is testing the safety and effectiveness of a targeted therapy in combination with chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults.
This trial is treating patients with synovial sarcoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Eli Lilly and Company
This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the development of new treatments for paediatric and young adult participants with cancer. Eligible patients will be randomised intravenous Gemcitabine and Docetaxel chemotherapy with or without Ramucirumab, for the treatment of their cancer. Participation in this trial could be for longer than 12 months, depending on how the participant and the participant's tumour responds.
Recruiting Hospitals Read More